Andrea Giuffrida

Professor, Pharmacology
Doctor, UT Health Science Center at San Antonio

Phone+1-210-567-3720
Emailgiuffrida@uthscsa.edu

6554 Citations
36 h-Index

If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Andrea Giuffrida is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

2 Similar Profiles

Endocannabinoids Medicine & Life Sciences

Cannabinoids Medicine & Life Sciences

Schizophrenia Medicine & Life Sciences

Dyskinesias Medicine & Life Sciences

Cannabinoid Receptor Agonists Medicine & Life Sciences

Parkinson Disease Medicine & Life Sciences

Cannabinoid Receptors Medicine & Life Sciences

Orthoptera Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2004 2016

2 Finished

Endocannabinoid transmission in schizophrenia

Giuffrida, A.

National Institutes of Health

6/1/11 → 3/31/16

Project: Research project

Endocannabinoids

Schizophrenia

Cannabinoid Receptor CB1

Dronabinol

Pharmaceutical Preparations

Role of Endocannabinoids in Levodopa-Induced Dyskinesias

Giuffrida, A.

National Institutes of Health

12/15/04 → 1/31/14

Project: Research project

Endocannabinoids

Dyskinesias

Levodopa

Cannabinoid Receptor Agonists

Basal Ganglia

Research Output 1986 2018

6554 Citations
36 h-Index
78 Article
4 Chapter

9 Citations (Scopus)

Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility

Aguilar, D. D., Giuffrida, A. & Lodge, D. J., Apr 1 2018, In : International Journal of Neuropsychopharmacology. 21, 4, p. 393-403 11 p.

Research output: Contribution to journal › Article

Cannabinoids

Dopaminergic Neurons

Rodentia

Schizophrenia

Psychotic Disorders

4 Citations (Scopus)

The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: Further evidence for transporter-mediated endocannabinoid release

Seillier, A. & Giuffrida, A., Mar 1 2018, In : Neuropharmacology. 130, p. 1-9 9 p.

Research output: Contribution to journal › Article

Endocannabinoids

Cannabinoids

Interpersonal Relations

Cannabinoid Receptor CB1

2-(2-(5-bromo-1H-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3H)-quinazolinone

1 Citation (Scopus)

Ventral hippocampal overexpression of Cannabinoid Receptor Interacting Protein 1 (CNRIP1) produces a schizophrenia-like phenotype in the rat

Perez, S. M., Donegan, J. J., Boley, A. M., Aguilar, D. D., Giuffrida, A. & Lodge, D. J., Jan 1 2018, (Accepted/In press) In : Schizophrenia Research.

Research output: Contribution to journal › Article

Receptor-Interacting Protein Serine-Threonine Kinases

Cannabinoid Receptors

Schizophrenia

Phenotype

Hippocampus

Anxiety does not contribute to social withdrawal in the subchronic phencyclidine rat model of schizophrenia

Seillier, A. & Giuffrida, A., Jul 12 2017, (Accepted/In press) In : Behavioural Pharmacology.

Research output: Contribution to journal › Article

Phencyclidine

Schizophrenia

Anxiety

Diazepam

Cannabinoid Receptor Agonists

1 Citation (Scopus)

The Endocannabinoid System and Parkinson Disease

Giuffrida, A. & Martinez, A., May 16 2017, The Endocannabinoid System: Genetics, Biochemistry, Brain Disorders, and Therapy. Elsevier Inc., p. 63-81 19 p.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Endocannabinoids

Parkinson disease

Parkinson Disease

cannabinoids

Cannabinoids